Klaria Pharma Holding AB (publ.) (KLAR.ST)
SEK 0.29
(-8.63%)
SEK 0.29
(-8.63%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.36 SEK | 67.27% |
| 2022 | -1.10 SEK | -13.4% |
| 2021 | -0.97 SEK | 12.61% |
| 2020 | -1.11 SEK | -54.17% |
| 2019 | -0.72 SEK | 13.25% |
| 2018 | -0.83 SEK | -124.32% |
| 2017 | -0.37 SEK | 17.78% |
| 2016 | -0.45 SEK | -50.0% |
| 2015 | -0.30 SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.11 SEK | 0.0% |
| 2024 Q1 | -0.11 SEK | -23.73% |
| 2023 Q2 | -0.09 SEK | -47.13% |
| 2023 Q3 | -0.10 SEK | -5.37% |
| 2023 FY | - SEK | 67.27% |
| 2023 Q4 | -0.09 SEK | 11.1% |
| 2023 Q1 | -0.06 SEK | 70.68% |
| 2022 Q2 | -0.26 SEK | 33.33% |
| 2022 Q1 | -0.39 SEK | 20.41% |
| 2022 Q4 | -0.22 SEK | 18.52% |
| 2022 FY | - SEK | -13.4% |
| 2022 Q3 | -0.27 SEK | -3.85% |
| 2021 Q3 | -0.28 SEK | 3.45% |
| 2021 Q2 | -0.29 SEK | -196.67% |
| 2021 Q4 | -0.49 SEK | -75.0% |
| 2021 FY | - SEK | 12.61% |
| 2021 Q1 | 0.30 SEK | 183.33% |
| 2020 Q3 | -0.26 SEK | -18.18% |
| 2020 FY | - SEK | -54.17% |
| 2020 Q4 | -0.36 SEK | -38.46% |
| 2020 Q2 | -0.22 SEK | 26.67% |
| 2020 Q1 | -0.30 SEK | -76.47% |
| 2019 Q3 | -0.22 SEK | 8.33% |
| 2019 Q2 | -0.24 SEK | -275.59% |
| 2019 Q1 | -0.06 SEK | 87.22% |
| 2019 FY | - SEK | 13.25% |
| 2019 Q4 | -0.17 SEK | 22.73% |
| 2018 Q1 | -0.12 SEK | 14.29% |
| 2018 FY | - SEK | -124.32% |
| 2018 Q3 | -0.11 SEK | 21.43% |
| 2018 Q2 | -0.14 SEK | -16.67% |
| 2018 Q4 | -0.50 SEK | -354.55% |
| 2017 Q2 | -0.11 SEK | -12.02% |
| 2017 Q4 | -0.14 SEK | -269.39% |
| 2017 Q3 | -0.04 SEK | 65.55% |
| 2017 FY | - SEK | 17.78% |
| 2017 Q1 | -0.10 SEK | 1.8% |
| 2016 Q3 | -0.10 SEK | 28.57% |
| 2016 FY | - SEK | -50.0% |
| 2016 Q4 | -0.10 SEK | 0.0% |
| 2016 Q1 | -0.12 SEK | 0.0% |
| 2016 Q2 | -0.14 SEK | -16.67% |
| 2015 Q1 | -0.01 SEK | 0.0% |
| 2015 Q2 | -0.05 SEK | -626.03% |
| 2015 Q3 | -0.05 SEK | 11.13% |
| 2015 Q4 | -0.12 SEK | -154.78% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AcuCort AB | -0.16 SEK | -125.0% |
| AlzeCure Pharma AB (publ) | -0.60 SEK | 40.0% |
| BioGaia AB (publ) | 3.62 SEK | 109.945% |
| Enzymatica AB (publ) | -0.28 SEK | -28.571% |
| Enorama Pharma AB (publ) | -1.61 SEK | 77.64% |
| Gabather AB (publ) | -0.65 SEK | 44.615% |
| Moberg Pharma AB (publ) | -1.33 SEK | 72.932% |
| Nanexa AB (publ) | -1.09 SEK | 66.972% |
| Newbury Pharmaceuticals AB (publ) | -0.72 SEK | 50.0% |
| ODI Pharma AB | 0.02 SEK | 1638.462% |
| Orexo AB (publ) | -3.73 SEK | 90.349% |
| Probi AB (publ) | 1.48 SEK | 124.324% |
| Swedencare AB (publ) | 0.37 SEK | 197.297% |
| Swedish Orphan Biovitrum AB (publ) | 7.47 SEK | 104.819% |
| Toleranzia AB | -0.06 SEK | -542.857% |
| Vivesto AB | -0.74 SEK | 51.351% |